IMPORTANCE Current recommendations for patients with cirrhosis are to undergo surveillance for hepatocellular carcinoma (HCC) with ultrasonography (US) every 6 months. However, the sensitivity of US screening to detect early-stage HCC is suboptimal. Magnetic resonance imaging (MRI) with liver-specific contrast may detect additional HCCs missed by US in high-risk patients with cirrhosis.
H epatocellular carcinoma (HCC) is the fifth most common cancer and the second largest cause of cancer mortality in the world. 1 Hepatocellular carcinoma has been the fastest-rising cause of cancer-related deaths in Western countries during the past 2 decades and is expected to increase further in the next decade. 2, 3 Hepatocellular carcinoma usually develops in patients with cirrhosis. 2, 3 With the decrease in mortality by complications of cirrhosis, HCC is becoming the leading cause of death among patients with cirrhosis. [2] [3] [4] The prognosis of patients with HCC is extremely poor with the 5-year survival rate below 20%. 2, 5 The prognosis largely depends on tumor stage, and curative treatments are available only for patients diagnosed when the cancer is at an early stage. Even for patients with early stage HCC, the chance of liver transplantation is often limited owing to donor shortage, and surgical resection is seldom possible because of considerable portal hypertension. Thus, the only curative treatment option is local ablation in many cases, which highlights the importance of surveillance to detect HCCs at a very early stage (a single lesion <2 cm). 6, 7 Currently, ultrasonography (US) at 6-month intervals is recommended for the surveillance of patients at risk to detect HCC at an early stage. [8] [9] [10] However, the sensitivity of US is suboptimal. [11] [12] [13] [14] Moreover, the sensitivity of US may be particularly impaired in those at highest risk of developing HCC because of the very nodular liver. [13] [14] [15] [16] Given the limited efficacy of US, other imaging techniques, such as computed tomography (CT) or magnetic resonance imaging (MRI) have been suggested for the surveillance of HCC in patients at high risk. 15 In diagnostic setting, MRI using a liver-specific contrast agent, gadoxetic acid, has been shown to be superior to dynamic CT or MRI enhanced by other types of contrast agents for detecting and characterizing liver lesions in the intrahepatic staging workup of HCC. [17] [18] [19] However, to our knowledge, there is no data on the use of MRI in the screening or surveillance setting. To determine the extent to which MRI with liver-specific contrast detects additional HCCs missed by US screening, we screened 407 high-risk patients with paired US and MRI at 6-month intervals for 3 rounds.
Methods

Study Population
This prospective study was conducted at Asan Medical Center, an academic tertiary care center in Korea (The PRIUS study, ClinicalTrials.gov ID NCT01446666). Study participants were recruited between November 2011 and August 2012. The inclusion criteria for participation were an age of 20 years or older and the presence of cirrhosis with an estimated annual HCC risk of more than 5%. Cirrhosis was diagnosed histologically and/or radiologically. The risk of HCC was estimated by using a model 20 with some modifications as follows: risk index = 1.41 (if the age is 50 years or older) + 1.65 (if the prothrombin activity is ≤75%) + 0.92 (if the platelet count is <100 x 10 3 /mm 3 ) + 0.74 (if anti-hepatitis C virus antibody or hepatitis B virus surface antigen test is positive). The risk index greater than 2.33 was estimated to correspond to an annual risk of developing HCC of more than 5%.
Other eligibility criteria included Eastern Cooperative Oncology Group performance status of 0 or 1, and absence of previous history or current suspicion of HCC. The absence of HCC had been evaluated by US, dynamic CT scan, or MRI within 6 months before enrollment. Patients with Child-Pugh class C liver function or an estimated glomerular filtration rate of less than 30 mL/min/1.73 m 2 were excluded.
The study was approved by the institutional review board of Asan Medical Center. All participants gave written informed consent and they were not compensated for participating. The trial protocol is provided in Supplement 1.
Study Protocol
The patients were evaluated by 3 rounds of screening tests with paired US and gadoxetic acid-enhanced MRI at 6-month intervals ( Figure 1 ). The first screening round was performed at 6 months after their most recent imaging session before enrollment.
Both US and MRI were performed on the same day whenever possible, or within 7 days of one another. Liver MRI was performed with a 1.5-T scanner (Magnetom Avanto; Siemens). Gadoxetic acid (Primovist; Bayer) was administered at a dose of 0.025 mmol/kg. Axial T1-weighted images of the arterial, portal, delayed, and hepatobiliary phases were obtained at 4-mm slice thickness.
Ultrasonographic examinations and MRI interpretations were allocated by an independent research coordinator (D.K.K.) to different radiologists (S.Y.K., S.J.L., H.J.W., or J.H.B.) who specialized in liver imaging with substantial expertise. Radiologists were blinded to the findings of the other imaging modality of the same and previous screening rounds. The findings of MRI and US were recorded in a predefined standardized way on a 5-point scale for MRI or 4-point scale for US, indicating the likelihood of HCC: highly suggestive, suspicious, equivocal, to help guide the biopsy. The confirmation of HCC was based on the results of histologic examination and/or typical CT images (nodule >1 cm with arterial hypervascularity and portal/ delayed-phase washout) as recommended by practice guidelines. 8, 17 Hepatocellular carcinoma stages were defined by the Barcelona Clinic Liver Cancer (BCLC) staging system: very early stage as single nodule smaller than 2 cm; early stage HCC as a single 2-to 5-cm lesion or 2 to 3 lesions each smaller than 3 cm. 8, 10 Follow-up At 6-months after the last screening round, all study patients were followed up with dynamic CT scans to exclude falsenegative findings of the last screening examinations. After then, study participants were followed up for at least 2 years for vital status. Study participants who completed at least 1 paired screening examination but who left the study for any reason before completing 3 screening rounds were also followed up.
Statistical Analysis
The primary end point was detection rates of US and MRI examinations for patients with HCC. A sample size of 380 (including 19 predicted HCC incidences) was calculated to achieve 81% power for the difference in HCC detection rate of 70% for US and 92% for MRI. Assuming a maximum drop-out rate of 10%, the required sample size was 423.
The results have been calculated on the basis of data on patients with HCC that were detected during the 3 rounds of screening tests and by follow-up dynamic CT scan 6 months after the last screening round. The HCC detection rate was defined as the number of patients with HCC detected by a given modality divided by the total number of patients with HCC detected by all modalities and by follow-up dynamic CT scan. The false-positive rate was defined as the number of tests with positive findings by a specific imaging modality in patients without an HCC; and the positive predictive value was the number of true-positive test results in patients with the positive tests in a specific modality.
Differences in the relative HCC detection rate and falsepositive rate of each modality were compared using the McNemar test. Survival of the patients was calculated from the date of first screening examination to the date of death or of last follow-up (June 30, 2015).
All reported P values are 2-sided and are not adjusted for multiple testing. All statistical analyses were performed using R software (v3.1.1, R project).
Results
Study Population
Among 423 patients with cirrhosis who consented to the study, 407 patients who received at least 1 pair of screening tests with US and MRI constituted the study cohort ( Figure 1 ). The median (interquartile range [IQR]) age at entry was 56 (52-62) years, and the proportion of patients with Child-Pugh class A was 78.6% (Table 1) . After enrollment, 49 patients withdrew from further participation mostly owing to logistic problems (n = 38), and 10 died of liver failure without HCC.
Of 1100 screening rounds, 762 (69.3%) of the US and MRI examinations were done on the same day, and only 10 (0.9%) were more than a week apart (maximum 13 days).
HCC Detection
In 1100 screening rounds of paired US and MRI, HCC was diagnosed in 38 patients. In addition, 5 patients were diagnosed with HCC at follow-up CT scan 6 months after negative findings on the last screening round with US and MRI ( Figure 1 ).
Figure 1. Study Profile
There were no interval cancers that were detected by clinical symptom or by unscheduled examinations between 2 rounds of screening after negative findings on screening. Thus, the total number of patients with HCC was 43 during median follow-up of 1.5 years, and the overall incidence rate of HCC was 8.5 per 100 patient-years.
Of the 43 patients with HCC, 39 showed typical features of HCC on dynamic CT images, and others were diagnosed pathologically. Pathological diagnosis of HCC was possible in 20 patients. Biopsy was unobtainable in the others because the nodules were not visualized by US or the location was deemed risky to target.
Of the 43 patients, 32 (74.4%) had very early-stage (single nodule <2 cm) and 10 (23.3%) had early-stage HCC (single 2-5 cm or 2-3 lesions each <3 cm). Only 1 patient had advanced stage HCC of 3.5 cm size with portal vein invasion that was detected by both of US and MRI at the first screening round ( Table 2) .
Performance of the Screening Methods
The positive screening criterion was category 4 or 5 on US or MRI. Of the 43 patients with HCCs: 1 was detected by US only, 26 by MRI only, 11 by both, and 5 were missed by both and were detected by follow-up CT scan ( Table 3) . The overall HCC detection rates of US and MRI were 27.9% and 86.0%, respectively (P < .001). For very early stage cancers only, the respective HCC detection rates were 27.3% and 84.8% (P < .001). The false-positive rates were 5.6% (59/1057) for US, which was significantly higher than the 3.0% (32/1057) for MRI (P = .004). Among 71 positive findings by US, 12 patients were confirmed to have HCC, giving a positive predictive value of 16.9%. Among 69 positive findings by MRI, 37 cases were confirmed as having HCC, giving a positive predictive value of 53.6%.
The area under the receiver operating characteristic curve (AUROC) for MRI was 0.93 (95% CI, 0.87-0.98), which was significantly higher than that for US (0.62; 95% CI, 0.55-0.69; P < .001) (eFigure 1 in Supplement 2).
Among the 59 false-positive findings on US, 27 lesions were confirmed as pseudolesions that did not have any matched lesions on follow-up CT and MRI, 20 were cirrhosis-related nodules, 4 were exophytic hepatic parenchyma, 3 were complicated cysts, and 1 was abnormal vasculature. Out of the 32 falsepositive findings on MRI, 12 were abnormal vasculature, 8 were cirrhosis-related nodules, 7 were pseudolesions that did not have any matched lesions on follow-up CT and MRI, 3 were considered as inflammatory lesions, and 2 were hemangiomas.
Among several clinical factors and imaging characteristics, subcapsular location of the HCC was the only significant factor for the false-negative findings by US (P = .02) (eTable 3 in Supplement 2). Among 20 HCC nodules located at subcapsule, only 2 were detected by US. A representative case is shown in eFigure 2 in Supplement 2.
Six patients with HCC had false-negative findings by MRI, and 1 case was detected by US. The lesion was located close to the inferior vena cava and right hepatic vein, and could be identified on a retrospective review of the MRI images, suggesting misinterpretation by a human error (eFigure 3 in Supplement 2). The other 5 lesions were missed by MRI and US, and were identified later on follow-up CT scans obtained 6 months after the study. On a retrospective review of MRI images, 4 of the corresponding lesions were detectable, but none of them showed typical vascular patterns of HCC on the last round of MRI (eFigures 4 and 5 in Supplement 2).
Treatment and Survival of Patients With HCC
Of the 43 patients with HCC, 29 (67.4%) received potentially curative treatments, such as liver transplantation, surgical resection, and local ablation (Table 2) .
Patients were followed up for a mean of 3.3 years from the date of first screening examination to monitor survival 
Discussion
The results of our prospective study support our hypothesis that MRI with liver-specific contrast is more sensitive than US to detect early stage HCC in high-risk patients with cirrhosis. For very early stage HCC (single lesion <2 cm), MRI screening yielded a detection rate of 84.8%, significantly higher than the 27.3% detected by US. Magnetic resonance imaging also showed a significantly lower false-positive results rate and a significantly higher positive predictive value than US.
The proportion of patients with very early stage and early stage HCC was strikingly high in our study population (97.7%). Consistent with that finding, the patients in our study group also had a high chance of receiving curative treatments (67.4%) and a favorable rate of survival. The 3-year survival rate of 86% in our study patients with HCC was obtained despite the severely limited access to liver transplantation.
Only 27.9% of the cancers were detected by US, which is far lower than the detection rates reported in previous metaanalyses (63%). 11 A possible explanation would be that MRI screening was able to detect tumors far earlier in their development than US, thus reducing the apparent HCC detection rate of US compared with MRI, with which 74.4% of HCC patients were detected at very early stage (single nodule <2 cm). In fact, our results are similar to the previous prospective studies of patients with advanced cirrhosis, which reported that US detected only about 20% of cases of HCC at a very early stage. 13, 16 Another explanation for the poor sensitivity of US may be that patients at particularly high-risk of HCC usually have inherent distortions of the liver parenchyma by cirrhosis that may obscure or, conversely, falsely simulate HCC at US imaging. [13] [14] [15] [16] The fact that we recruited only patients with advanced cirrhosis, therefore, may be reflected in our results. Another drawback of US screening was that it had a significantly higher false-positive rate than MRI, generating more findings that required unnecessary additional recall examinations with dynamic CT and/or biopsy, which caused additional cost and potential harm to patients. The addition of AFP marginally improved the discriminating capacity of US, but not that of MRI. A major consideration in implementing an MRI surveillance program for HCC would be the cost-effectiveness of the intervention. In general, the cost-effectiveness of a cancer screening program relies on multiple factors including the characteristics of the population under surveillance, the test's performance, the test's cost, and the availability of treatments that substantially extend survival of the patients. 22, 23 With the limited availability of liver transplantation, surveillance for HCC would only be cost-effective in patients with Child-Pugh Class A. Considering these points, we excluded patients with ChildPugh Class C.
Limitations
This study should be interpreted within its limitations. First, pathological confirmation of HCC was not possible in all patients, mostly because of the inability to obtain biopsy samples by US-guidance. Dynamic CT, which was used for the diagnosis of HCC, has lower sensitivity than MRI with liver-specific contrast. [17] [18] [19] 24 However, the CT diagnostic criteria we used (arterial hypervascularity and portal/delayedphase washout) are highly specific for HCC in patients with cirrhosis, as recommended by practice guidelines. 8, 10 Therefore, there would be little possibility for false diagnosis or overdiagnosis of HCC in our study patients. Second, the high survival rate of our patients with HCC might be overestimated by lead-time bias. However, the possibility is low because high proportion of patients received curative treatment, and only 1 patient died from HCC progression during follow-up for more than 2 years. Third, our findings should also be viewed in the light of the different degrees of resources needed to offer MRI and US screening. MRI availability is limited and it requires more personnel, costly facilities, and more consumables than US. Despite the fact that MRI is in increasing use for HCC surveillance in clinical practice, 25 
Conclusions
This study shows that, in patients with cirrhosis at high risk of HCC, screening using MRI with liver-specific contrast resulted in a higher HCC detection rate and lower falsepositive results compared with US. With MRI screening, most of the cancers detected were at very early stage, which was associated with a high chance of curative treatments and favorable survival of patients. Since the annual risk of developing HCC is not uniform across all patients with cirrhosis, the tailored surveillance strategy based on the individual HCC risks may enable delivery of precision medicine to patients and improve their clinical outcomes. Whether surveillance with liver-specific contrast-enhanced MRI would reduce mortality from HCC in high-risk patients requires further investigation. 
ARTICLE INFORMATION
Confidentiality
The information contained in this document is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Institutional Review Board or Independent Ethics Committee. The information is only to be used by you in connection with authorized clinical studies described in the protocol. You should not disclose any of the information to others without written authorization from the investigator, except to the extent necessary to obtain informed consent from those persons to whom the drug may be administered. The first round of screening imaging tests will be performed at 6 months after their last clinical imaging study (US or dynamic-CT or MRI). All study subjects will be evaluated by 3 rounds of tests with both US and Primovist-MRI at the interval of 6 months. Whenever possible, both US and Primovist-MRI will be performed on the same day or within a time frame of 1 week. After the completion of the 3 strategic evaluation rounds, at least 6 months of clinical follow-up data with dynamic-CT images will be collected to record occurrence of HCC. Exclusion criteria Patients will be excluded from the study for any of the following reasons:
1) History or suspected malignancy of any type 2) Significant medical comorbidities in which survival is predicted to be less than 3 years 3) Estimated GFR <30 mL/min/1.73m 2 4) Child-Pugh class C liver function 5) Precautions for MRI (cardiac pacemaker, ferromagnetic implants, etc.) 6) Severe claustrophobia that may interfere with protocol compliance. 7) Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with the completing the study.
Statistical Analyses
Sample Size Justification Sample size required for this study was estimated using PASS version 11 (Kaysville, Utah, USA) with following assumptions, -Estimated annual HCC incidence = 5% -HCC detection rate by US = 70% -HCC detection rate by Primovist-MRI = 92% -Power (1-beta) = 0.8 -Alpha error = 0.05 -Intra-individual analysis A total sample size of 380 (which includes 19 subjects with the disease) achieves 81% power to detect a change in detection rate from 0.7 to 0.92 using a one-sided binomial test. The target significance level is 0.05. If we consider the maximum drop out rate of 10%, the required sample size will be 423. Statistical Analytic Plan HCC detection rate will be defined as the number of patients with HCCs detected by a given modality divided by the total number of patients with HCCs detected by all two modalities plus interval cancers and cancers detected by follow-up CT scan. False referral rate (i.e., examinations leading to a negative recall process) will be defined as the number of false-positive results divided by the sum of truenegative and false-positive results. Differences in the relative HCC detection rate and false referral rate of each modality will be compared with McNemar test. The positive predictive value for each modality will be defined as the number of patients with confirmed HCCs divided by the number of positive tests. Person-years at risk will be calculated from the date of the first screening examination to the date of HCC diagnosis; the date that a patient stopped surveillance; or the date of follow-up CT scan at 6-month after the third round. Survival of the patients with HCC will be calculated from date of diagnosis of HCC to date of death or of last follow-up. A two-sided P value of less than 0.05 will be considered to indicate statistical significance. Statistical analyses will be performed using IBM SPSS software (IBMCorp., Armonk, NY, USA) and R software (R Foundation for Statistical Computing, Vienna, Austria; www.r-project.org). 
Study Phase
Biomarker Phase IV (Definition by US National Cancer Institute)
Study Site and Investigator
Investigator Address
Asan Medical Center Young-suk Lim 88, Olympic-ro 43-gil, Songpa-gu, Seoul, Korea
Study Objectives and Background
Study Objectives
The objective of this study is to evaluate the detection rate of ultrasonography (US) and Primovistmagnetic resonance imaging (MRI) for hepatocellular carcinoma (HCC)
Primary Endpoint
-The detection rate for HCC during three-rounds of paired evaluations with US and MRI at 6-months intervals 
Secondary Endpoints
Background
HCC is the fifth most common cancer worldwide and accounts for 5.6% of all cancers, with an increasing incidence in Europe and the United States. [1] [2] [3] [4] [5] HCC has been the fastest-rising cause of cancer-related deaths in Western countries during the past two decades and is expected to increase further in the next decade. [4] [5] [6] Cirrhosis, particularly when related to viral hepatitis, is the most notable risk factor for HCC and is found in nearly 80-90% of cases. 2, 6 The stage of disease at the time of diagnosis largely determines the effectiveness of treatment. The treatment of advanced HCC continues to be primarily palliative; and curative options are only available for patients with early stage HCC. In patients with preserved hepatic function and single tumors, surgical resection has provided 5-year survival rates of 70%. 7 Similarly, liver transplantation for tumors meeting the Milan criteria (one nodule <5 cm or three nodules each <3 cm in diameter) has a 5-year survival rate of nearly 74%. [7] [8] [9] In patients with early-stage disease who are not amenable to resection or transplantation, radiofrequency ablation has demonstrated 5-year survival rates of 37%. 7 These survival rates are in stark contrast to the average survival of <1 year reported for advanced HCC. 10 Unfortunately, less than 30% of patients are diagnosed early enough to meet criteria for resection, transplantation, or local ablation.
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Surveillance strives to detect HCC at an early stage when it is amenable to curative therapy to reduce mortality. Current practice guidelines recommend surveillance of cirrhotic patients with US every 6 months. 12 However, few trials have prospectively evaluated the utility of US as a surveillance test. US has been reported to have a detection rate of between 65% and 80% and specificity of about 90% when used as a screening test. 12, 13 However, with the advancement of cirrhosis, the detection rate of US decreases, while the risk for HCC increases. [12] [13] [14] Gadoxetic acid (Primovist ® )-enhanced MRI of the liver has already been demonstrated to be of Clinical Research Protocol -PRIUS Study Principal Investigator: Lim, Young-Suk clinical value for local staging before HCC surgery and for the assessment of patients with inconclusive conventional imaging findings. [15] [16] [17] [18] [19] [20] [21] [22] [23] The detection rate of Primovist-MRI has been known to be as high as 90-95%, which is significantly higher than US or multiphase CT scan. Compared with CT, MRI does not have radiation exposure, which is a meaningful merit to be used as a surveillance test. However, MRI has never been considered for surveillance or screening of HCC.
Thus, the hypothesis to be proved by this study is as follows; Primovist-MRI should show significantly higher detection rate compared to US for HCC when both of these imaging modalities are used with the interval of 6 months in patients with cirrhosis at high risk of developing HCC.
Study Design
Prospective intra-individual comparative cohort study
Projected Duration of the Study
From the date of instuitional review board (IRB) approval to 31 DEC 2019 However, duration of the study could be extended.
Target Disease
Patients with Liver Cirrhosis at High-Risk for developing HCC ; 'High-Risk for HCC' will be defined by a model previously proposed by other investigators with some modifications as follows; The identification of hepatic surface nodularity and splenomegaly
The identification of portal collaterals or ascites 2) Older than 20 years of age 3) Absence of previous history or current suspicion of HCC -Absence of HCC should be identified by liver US, dynamic CT, or contrast-enhanced MRI within 6 months prior to screening 4) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1 5) Patient is able to comply with scheduled visits, evaluation plans, and other study procedures. 6) Patient is willing to provide written informed consent.
Exclusion criteria
Patients will be excluded from the study for any of the following reasons:
1) History or suspected malignancy of any type 2) Significant medical comorbidities in which survival is predicted to be less than 3 years 3) Estimated GFR < 30 mL/min/1.73m 
Study Procedures and Methods
Assignment of subjects
For this intra-individual comparative analysis, each study patient will be evaluated by both US and Primovist-MRI. Whenever possible, all 3 screening modalities will be performed on the same day or within a time frame of 1 week. All US examinations and MRI interpretations will be allocated by an independent research coordinator (D.K.K.) to different co-investigators who are board-certified abdominal radiologists (S.Y.K., S.J.L, H.J.W, or J.H.B) with substantial expertise in liver imaging.
Blinding
Observer-blind; Each imaging study will be read and scored independently by a different radiologist. The readers will be blinded to the findings of the other imaging modality of the same and previous screening rounds. 
Study Procedures 1) Screening visit (W-26~W0)
Details of Imaging Methods
1) Liver US
US examinations will be obtained using a convex broadband probe (SC6-1) of a US system (Supersonic Imagine SA; Aixplorer, Aix-en-Provence, France). One of co-investigators who are board-certified abdominal radiologists (S.Y.K., S.J.L, H.J.W, or J.H.B) with substantial expertise in liver imaging will evaluate the entire liver thoroughly and interpret the US study.
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2) Primovist-MRI
Liver MRI will be performed on a 1.5 T MR imaging system (Magnetom Avanto; Siemens Medical Solutions, Erlangen, Germany) with dedicated six-channel torso array coils. Patients will undergo liver MRI using a widely used MRI protocol, 25, 26 which consists of non-enhanced MRI (breath-hold dual gradient-echo T1-weighted imaging, breath-hold half-Fourier acquisition single shot TSE T2-weighted imaging, respiratory-triggered TSE T2-weighted imaging, and diffusionweighted imaging with a respiratory-triggered single-shot echo planar sequence) and contrastenhanced MRI. Contrast-enhanced MRI will be done using a fat-suppressed, three-dimensional, spoiled gradient echo T1-weighted sequence (volumetric interpolated breath-hold examination, VIBE; Siemens) at a 4mm-slice thickness. After intravenous injection of 0.1mL/kg body weight of Gd-EOB-DTPA at 1mL/sec followed by a 20-mL saline flush, the following four phases will be obtained: the arterial phase (determined using a test-bolus method), venous phase (25 seconds after completion of arterial phase images), delayed phase (three minutes following contrast injection), and hepatobiliary phase images (20 minutes after contrast injection).
3) Dynamic 4-Phase CT
CT scans will be obtained with a 64 multidetector CT scanner (LightSpeed VCT, GE medical Systems, Milwaukee, WI) in the unenhanced, arterial, portal venous, and delayed phases. Patients were given 2 mL/kg of iopromide (Ultravist 370; Schering, Berlin, Germany) intravenously at a rate of 4 mL/sec via the antecubital vein. Arterial phase images were obtained using a bolus tracking technique with a trigger enhancement threshold at the upper abdominal aorta of 100 HU. After the threshold is reached, a diagnostic delay time of 25 seconds will be used for the arterial phase. Portal and delayed phase images will be obtained 72 and 180 seconds, respectively, following contrast injection.
Interpretation and Recording of Results
All US examinations and MRI interpretations will be allocated by an independent research coordinator to different radiologists. The readers will be blinded to the findings of the other imaging modality of the same and previous screening rounds.
1) Liver US
The radiologist, who performs the US scan, will interpret the US study. Results of US exams will be scored according to a predefined structured report on a four-point scale indicating the likelihood of HCC (suspicious, category 4; equivocal, category 3; probably benign, category 2; or definitely benign, category 1) based on previous studies (Appedix 3). [27] [28] [29] The structured report system will be integrated in a picture archiving and communication system (PACS) and an electronic medical record system in our institution in order to automatically categorize the image interpretation (Appendix 4).
2) Primovist-MRI
Interpretation of MRI will be also scored using a predefined structured report on a five-point scale indicating the likelihood of HCC (highly suggestive, category 5; suspicious, category 4; equivocal, category 3; probably benign, category 2; or definitely benign, category 1), modified from the Liver Imaging Reporting and Data System (LI-RADS) Version1.0_March2011 proposed by the American College of Radiology (http://www.acr.org/Quality-Safety/Resources/Archive). The structured report system will be integrated in a PACS and an electronic medical record system in our institution in order to automatically categorize the image interpretation (Appendix 3 & 4).
Recall Process
When one of the US or MRI examinations detected a nodule scored as category 5 or 4, further investigation with dynamic 4-phase CT scan will be performed within3 months. A biopsy will be also tried whenever possible. If the findings on US and Primovist-MRI are different, the recall process will be followed by the higher grade in either imaging. The diagnosis of HCC will be based on the results of a histologic examination. However, if the pathologic specimen will be unobtainable by any reason, the diagnosis of HCC will be made by CT images showing typical features of HCC, i.e., a nodule larger than 1 cm with arterial hypervascularity and portal-or delayed-phase washout. 10 Patients will not be offered subsequent surveillance tests unless the recall process confirmed the absence of HCC Surveillance based on the protocol will be performed in next round if HCC is not diagnosed by recall process.
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Patients with no suspicious lesion during the three screening rounds will undergo follow-up CT scan 6-month after the third screening round.
Safety Evaluation
Although Primovist has already been approved for MR contrast, any adverse events will be evaluated, recorded, and reported.
Definition of Adverse Events
All adverse events will be assessed and recorded on the adverse event (AE) case reporting form (CRF) page by the investigator. An AE is any untoward medical occurrence in a study patient, regardless of the potential relation with the use of a study drugs.
Assessment of AEs
All AEs occurring after initiation of clinical trial and until the end of follow-up/final visit should be recorded in the CRF.
Severe Adverse Events (SAEs)
A serious adverse event is any untoward medical occurrence that, at any dose:
Death or life-threatening events Hospitalization or prolongation of existing hospitalization Persistent or significant disability/incapacity Development of fetal anomalies Hospitalization for elective treatment of a pre-existing condition that did not worsen from baseline is not considered a SAE
Reporting Procedure
The principle investigator and sub-investigators have to notify IRB all SAEs during the study regardless of causal relationship. They must fax or e-mail the SAE form to the principal investigator and Asan medical center IRB within 24 hours of the investigator's acknowledgement of the event.
All the information about SAE should be reported to the principal investigator and IRB until they are completely resolved.
Intensity of AE
All AEs will be graded according to the Common Terminology Criteria of Adverse Event (CTCAE), version 4.0 grading scale.
Causal Relationship of AE
The following categories and definitions of causal relationship to the study drug should be used for 
Sample Size Justification
Sample size required for this study was estimated using PASS version 11 (Kaysville, Utah, USA) with following assumptions, -Estimated annual HCC incidence = 5% -HCC detection rate by US = 70% -HCC detection rate by Primovist-MRI = 92% -Power (1-beta) = 0.8 -Alpha error = 0.05 -Intra-individual analysis A total sample size of 380 (which includes 19 subjects with the disease) achieves 81% power to detect a change in detection rate from 0.7 to 0.92 using a one-sided binomial test. The target significance level is 0.05. If we consider the maximum dropout rate of 10%, the required sample size will be 423.
Statistical Analyses
Event will be defined as the diagnosis of patients with HCC during the entire study period. Personyears at risk will be calculated from the date of the first screening test to the date of diagnosis of HCC; the date that a patient stopped surveillance; or the date of follow-up CT scan at 6-month after the third round. An interval cancer will be defined as a HCC detected between two screening rounds after negative findings on preceding screening. HCC detection rate will be defined as the number of patients with HCCs detected by a given modality divided by the total number of patients with HCCs detected by all two modalities plus interval cancers and cancers detected by follow-up CT scan. False referral rate will be defined as the number of falsepositive results divided by the sum of true negative and false-positive results. Differences in the relative HCC detection rate and false referral rate of each modality will be compared with McNemar test. The positive predictive value for each modality will be defined as the number of patients with true positive test results in patients with the positive tests in a specific imaging category. A two-sided P value of less than 0.05 will be considered to indicate statistical significance. Statistical analyses will be performed using IBM SPSS software (IBMCorp., Armonk, NY, USA) and R software (R Foundation for Statistical Computing, Vienna, Austria; www.r-project.org).
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Discontinuation and Withdrawal
Subjects may be withdrawn from the study at the investigator's discretion in any of the following instances:
Development of a toxicity or adverse event which warrants drug discontinuation Vital violations of the clinical trial protocol The subjects refuse the administration of the study drugs or safety tests The subjects withdraw the agreement of participation of the trial Treatment after discontinuation or withdrawal will be determined by the investigator. In case of discontinuation or withdrawal due to adverse events or safety issue, subjects should be followed until full recovery and the events should be recorded in CRFs.
Protection of the Subjects
The investigational institutions should make sure that the necessary personnel and facilities to conduct the study are appropriately provided. The investigators should do their best for the safety of the study subjects. If serious adverse events occur during the trial, the investigators should notify IRB after taking adequate therapeutic measures. The responsible conduct of the study will be regularly monitored by the Human Research Protection Center of each participating sites.
Informed Consent, Agreement of Compensation, Post-Study Treatment
Patient Information and Informed Consent
The investigator is responsible for obtaining written informed consent from each participants after adequate explanation of the aims, methods, objectives, and potential hazards of the study and before undertaking any study-related procedures. The investigator must use the IRB-approved consent form for the written informed consent. Each informed consent will be appropriately signed and dated by the subject or the subject's legally authorized representative and the person obtaining the consent. A signed copy of the informed consent and any additional patient information must be given to each patient or the patient's legally accepted representative. If the subject or representative cannot read, an impartial witness is needed.
Compensation Available to the Patients in the Event of Trial Related Injury
In the event of health injury associated with this trial, the sponsor is responsible for compensation based on the contract.
Treatment of the Subjects after the End of the Clinical Trial
The subjects who have fulfilled the study would follow the standard treatment of liver cirrhosis. The subjects who are terminated in the middle of the study should receive other appropriate surveillance of HCC. After detection of HCC, treatment will be determined by the subjects' clinical status and at the physician's discretion.
Additional Considerations for the Study 14.1. Compliance and modification of the Clinical Trial Protocol
This study must be conducted according to the clinical trial protocol, including written informed consent approved by the IRB. All protocol modifications should be upfront discussed between the investigators. All protocol modifications, except those intended to reduce immediate risk to subjects, should be submitted to and approved by the IRB. Approvals must be obtained before changes can be implemented. In the event that modification applied to prevent immediate damage to the subjects before the IRB approval, they should be reported to the IRB as soon as possible.
Monitoring
Clinical Research Protocol -PRIUS Study Principal Investigator: Lim, Young-Suk Assigning the Data Safety and Monitoring Committee (DSMB) in charge of this trial, the DSMB will regularly visit and monitor the study sites before starting the study and during the whole study period. The monitor is responsible for routine review of the CRFs at regular intervals throughout the study to verify adherence to the protocol and the completeness, consistency, and accuracy of the data being entered on them. The monitor should have access to any subject records needed to verify the entries on the CRFs. The investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits are resolved.
Storage of the Documents and Data
The investigator must maintain all the documents and records of this study to be adequate and accurate, and should subsequently verify them. The investigator is responsible for maintaining and providing of the essential documents. The essential documents mean ones that allow evaluating conduct of the clinical trial. The clinical trial essential document will contain the protocol/amendments, CRF and query forms, IRB approval with correspondence, informed consent, and monitoring records and other appropriate documents and correspondence. Subject clinical source documents contain all the observed date, the records of clinical trial activities and all the reports and records for assessment and reconstruction of the clinical trial. Therefore subject clinical source documents should include the records of all the procedures conducted by the clinical trial protocol. All clinical study documents must be retained by the investigator until at least 3 years after the end of the study.
Confidentiality of the Data and Records of the Subjects
The investigator must assure that subjects' anonymity will be strictly maintained. The subjects should be accessed by only subject initials or an identification code. Their identities have to be protected from unauthorized parties. Only the investigators, study coordinators, those who conduct inspections, IRB, the director of Korea Food & Drug Administration (KFDA) can review the data of the subjects to verify the reliability and the study process within the range prescribed by the relevant provisions and without violating the confidentiality of research subjects. The likelihood of hepatocellular carcinoma (HCC) was based the Liver Imaging Reporting and Data System, version 1.0 (http://www.acr.org/Quality-Safety/Resources/LIRADS/Archive) after modifications. F/U, follow-up; HB, hepatobiliary; MRI, magnetic resonance imaging; SI, signal intensity. *Atypical cyst (or probable cyst), atypical hemangioma (or probable hemangioma), atypical focal fat deposition (or probable focal fat), atypical focal fat sparing (or probable focal fat sparing), hypertrophic pseudomass interpreted as probably benign, rounded perfusional alterations (nodular arterial phase hyperenhancement, NAPH), patchy (changed from "florid") perfusional alterations, atypical confluent fibrosis (probable confluent fibrosis), atypical focal scars (probable focal scars), some arterial-phase non-hyperenhancing atypical nodules progressively enhancing observations which do not meet the criteria in Category 3. † Cyst, hemangioma, focal fat deposition, focal fat sparing, hypertrophic pseudomass interpreted as definitely benign, wedge-shaped perfusional alterations, confluent fibrosis, focal scars, homogeneous siderotic nodules. Imaging features diagnostic of a benign entity including cyst, hemangioma, focal fat deposition, focal fat sparing, or hypertrophic pseudomass
The likelihood of hepatocellular carcinoma (HCC) was based on previous work 1-3 after modifications.
A. Overall HCC 
False Positive Rate
The difference between the area under the curves was significant between MRI and US in the detection of overall HCC (0. Data are n, n (%), or Mean ± standard deviation, unless otherwise specified. HCC, hepatocellular carcinoma: MRI, magnetic resonance imaging: NA, not applicable: US, ultrasonography * Maximum tumor diameter
In this 56-year-old woman with hepatitis B-associated cirrhosis, Round 3 gadoxetic acidenhanced MRI did not find any lesion suggestive of HCC (A-D). Another hypointense lesion in right lobe (A-D, indicated with arrowheads) was a hepatic cyst. However, the follow-up CT obtained 6 months after Round 3 MRI identified that a newly-developed 1.8 cm-sized lesion with arterial hypervascularity and wash-out on portal and delayed phase images (E-G, indicated with arrows). Therefore, the lesion was deemed to be incident HCC, which was confirmed later by surgical pathology. The hepatic cyst is also noted (E-G, indicated with arrowheads). In this 61-year-old man with hepatitis B-associated cirrhosis, Round 3 gadoxetic acid-enhanced MRI detected a 1.2 cm-sized arterial hypervascular nodule (A, indicated with arrow) in right hepatic dome which showed isointensity on portal, delayed, and hepatobiliary phase images (B-D). Thus, the lesion was not regarded as HCC. However, the follow-up CT obtained 6 months after Round 3 MRI found that the lesion showed interval growth up to 1.6 cm in diameter, arterial hypervascularity and wash-out on delayed phase images (E-F, indicated with arrows). The lesion was diagnosed as HCC. 
